Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $661.9 million.

  • Autolus Therapeutics' Liabilities and Shareholders Equity fell 2000.54% to $661.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year decrease of 155.3%. This contributed to the annual value of $782.7 million for FY2024, which is 10851.48% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Liabilities and Shareholders Equity of $661.9 million as of Q3 2025, which was down 2000.54% from $721.0 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity registered a high of $901.4 million during Q1 2024, and its lowest value of $263.8 million during Q3 2022.
  • In the last 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity had a median value of $451.0 million in 2023 and averaged $526.4 million.
  • In the last 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity plummeted by 2343.44% in 2023 and then skyrocketed by 10851.48% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Liabilities and Shareholders Equity stood at $405.6 million in 2021, then rose by 20.89% to $490.3 million in 2022, then dropped by 23.43% to $375.4 million in 2023, then surged by 108.51% to $782.7 million in 2024, then dropped by 15.43% to $661.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $661.9 million for Q3 2025, versus $721.0 million for Q2 2025 and $746.3 million for Q1 2025.